(Alliance News) - Scancell Holdings PLC on Tuesday said that it has completed the monotherapy dose finding arm of its multicentre Phase 1/2 ModiFY clinical trial, designed to treat cancer patients.
Scancell is a Nottingham, England-based cancer immunotherapies developer. Shares in the firm were trading 11% higher at 19.94 pence each in London on Tuesday morning.
ModiFY is a first-in-human Phase 1/2 basket trial investigating the use of Modi-1, the first candidate from Scancell's Moditope platform, to treat four different types of cancer: high grade serous ovarian carcinoma; triple negative breast cancer; head and neck squamous cell carcinoma; and renal cell carcinoma.
Scancell told investors on Tuesday that early data from the trial is encouraging.
The Modi-1 cancer vaccine showed a partial response and stable disease in patients with head and neck, high grade serous ovarian or triple negative breast cancers. No dose limiting toxicities were observed in the monotherapy dose escalation cohorts.
"We are highly encouraged with the early efficacy data we have achieved in the ModiFY clinical trial, and safety profile to date with patients receiving Modi-1. These results allow us to proceed with the monotherapy expansion cohorts and into the cohorts in combination with checkpoint inhibitors as planned," said Chief Executive Officer Lindy Durrant.
By Holly Beveridge; Alliance News reporter
Comments and questions to newsroom@alliancenews.com
Copyright 2023 Alliance News Ltd. All Rights Reserved.
Scancell Holdings (SCLP)